Roivant Sciences Ltd. (ROIV) research
Roivant Sciences Ltd.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $35.72
- As of
Roivant Sciences Ltd. (ROIV): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-18.
As of . Source: SEC EDGAR filings for ROIV. Method and limitations.
Share the ROIV intelligence card
See the full ROIV dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ROIV on one page. Preview it with sample data, then open it live with a free account.
Preview the ROIV dossierActive signals for ROIV
- highCONSENSUS_BUY
4 tracked funds increased ROIV this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 86% of ROIV (2026Q2)
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 67% of ROIV (2026Q2)
- highINSTITUTIONAL_SURGE
Point72 Asset Management, L.P. added +9338% to ROIV (2026Q2)
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 68% of ROIV (2026Q2)
FREE, NO ACCOUNT
Every signal on ROIV, as it fires
You are seeing 5 of 18 signals recorded on ROIV since 2026-05-17.
The five above landed across 2 days. The other 13 were recorded on 5 other days. 10 of the 18 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in ROIV (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| VIKING GLOBAL INVESTORS LPCUSIP G76279101 · 2026Q2 | $221.9M | 0.63% | , |
| CITADEL ADVISORS LLCCUSIP G76279101 · 2026Q2 | $197.3M | 0.02% | , |
| Point72 Asset Management, L.P.CUSIP G76279101 · 2026Q2 | $158.3M | 0.17% | , |
| D. E. Shaw & Co., Inc.CUSIP G76279101 · 2026Q2 | $105.2M | 0.05% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP G76279101 · 2026Q2 | $24.8M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP G76279101 · 2026Q2 | $779K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, ROIV
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
ROIV against its peers
ROIV's operating margin of -6235.7% ranks in the 3rd percentile of 18 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | ROIV | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 8.3M USD | 2.3B USD | 13 | 18 |
| Operating margin | -6235.7% | 17.6% | 3 | 18 |
| Net margin | -3629.2% | 13.1% | 3 | 19 |
| Return on equity | -6.6% | 7.9% | 28 | 19 |
| P / E | n/a | 31.8x | n/a | 11 |
Peers (22): RPRX, BNTX, INSM, INCY, ALNY, GMAB, UTHR, BIIB, ONC, RVMD, ASND, EXEL, NBIX, SMMT, BBIO, HALO, ARGX, MDGL, BMRN, NTRA, APGE, KRYS. Left out: IVBXF (no annual filing), SBMFF (no annual filing), CSLLY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (ROIV: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more ROIV signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to ROIVand get the insider, 13F, options, and confluence read in one view.